Physician profile
John M Brooks
NPI 1801890421
$1,319.49
in general payments reported to CMS, 2019-2025
22 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $163 · 2021: $267 · 2022: $149 · 2023: $160 · 2024: $123 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $528 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $528.31 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $315.86 | 2019-2025 | Trelegy Ellipta |
| Abbott Laboratories | $181.03 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $102.38 | 2019-2025 | Evenity, Prolia, Prolia |
| Astrazeneca Pharmaceuticals LP | $87.01 | 2021-2025 | Farxiga |
| Pfizer INC. | $81.93 | 2019-2025 | |
| Lilly USA, LLC | $81.73 | 2019-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $68.70 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $61.46 | 2019-2022 | |
| Exact Sciences Corporation | $49.20 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $39.67 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $39.29 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.54 | 2023 | Xifaxan, Trulance |
| Novo Nordisk INC | $25.65 | 2021-2023 | |
| Verona Pharma, INC. | $24.75 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $24.45 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $23.96 | 2024 | Nayzilam |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.71 | 2025 | Caplyta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.50 | 2025 | |
| Phathom Pharmaceuticals, INC. | $15.82 | 2023 | Voquezna |
| Biogen, INC. | $13.21 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.85 | 2022 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.